Introduction Globally, biosimilars are expected to play a key role in lowering healthcare costs and providing increased patient access to biological therapies. Given this, and in line with the European Union and World ...

Context: Medicaid is the primary payer for substance use disorder (SUD) treatment in the United States. While some policy changes have been well documented, the operational decisions that guide the implementation of ...